News

4 case histories highlight the physical and psychosocial burden of generalized pustular psoriasis.

As news of benzene contamination in benzoyl peroxide products continues to raise safety discussions, Steve Xu, MD, MSc, advocates for stricter regulations, increased research, and the consideration of safer acne treatment alternatives.

Researchers noted that ethical use of AR and VR in cosmetic care requires balancing technological benefits with patient safety and privacy.

The LIBERTY-AD PED-OLE study showed clinical remission for moderate to severe atopic dermatitis.

Researchers stated the dual-action therapy could offer a promising approach to treat progressive non-segmental vitiligo.

Learn more about the in-depth topics covered in the October 2024 acne supplement of Dermatology Times.

The minocycline hydrochloride extended release capsules (40 mg) represent a new standard of care for patients with rosacea.

Clinical trial exit interviews reveal detailed perspectives on disease burden for patients with chronic hand eczema.

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

Learn more about the in-depth topics covered in the October 2024 vitiligo supplement of Dermatology Times.

Christopher Bunick, MD, PhD, highlights rademikibart's next-generation efficacy, showing stronger IL-4Rα binding affinity in atopic dermatitis and asthma.

Click here to test your knowledge and read more about the treatment landscape of chronic hand eczema.

After 1year of dupilumab treatment, researchers reported 76.5% of patients achieved CR, with further improvement to 85.6% after 3 years.

Dermatology Times asked our readers to share what conferences they are looking forward to in the fourth quarter of 2024.

The phase 2a trial demonstrated the systemic treatment’s tolerable safety profile for patients with chronic and progressive hair loss.

Learn more about the in-depth topics covered in the October 2024 print issue of Dermatology Times.

Egeberg discusses promising new treatments and insights from recent clinical trials, highlighting significant advancements in chronic hand eczema and atopic dermatitis care presented at the EADV 2024.

Motivators like health benefits, altruism, and trust in clinicians enhance participant retention and adherence in melanoma research, according to MEL-SELF findings.

Dermatology Times is looking back on the top stories in dermatology from the month of October.

Dermatology Times is recapping our top expert interviews from the month of October.

Catch up on coverage from the 2024 Fall Clinical Dermatology Conference in Las Vegas, Nevada.

Bob Rhatigan, CEO of Merz Aesthetics, discusses the organization’s commitment to advancing the aesthetics industry through strategic partnerships, specialized training, and a growing portfolio of injectables and devices.

Designed to fill a gap in rosacea evaluation, the TRoSA scale provides an objective method for tracking telangiectasia severity, which could also be integrated with AI for automated assessments.

A pilot study monitored the disease management, technical challenges, and overall benefits for chronic spontaneous urticaria.

At Fall Clinical 2024, Christopher Bunick, MD, PhD, presented findings on the prevalence of systemic corticosteroid use among patients with atopic dermatitis and highlighted how those treated with upadacitinib achieved and sustained optimal skin clearance and itch relief long-term.

The study underscores the importance of addressing work-related concerns for patients with melanoma, advocating for effective communication about rehabilitation options.

In a Dermatology Times Case-Based Roundtable event, Pearl E. Grimes, MD, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

Manson Brown discusses Allergan Aesthetics' Science of Aging program, highlighting its role in shifting from anti-aging to pro-longevity in aesthetic medicine.

The nonsteroid 1% cream treatment demonstrated good response and tolerability in patients with PPP.

For mild to moderate alopecia areata, topical corticosteroids remain the most frequently prescribed first-line treatment among UK dermatologists.